

## Swiss government sponsored CTI/KTI R&D project

**May 15 2016** - The CTI/KTI project “Banking of human antibody repertoires for therapeutic use” was approved and starts in June 2016. The project runs for 24 months and includes academic partners from the ETH Zürich, University Hospital Zürich and the University Basel.

### About Memo Therapeutics AG

Memo Therapeutics is an innovator in the area of recombinant immunoglobulins and human-derived monoclonal antibodies. The technological core of Memo Therapeutics is MemoMAB™ – a technology enabling cost and time-effective molecular cloning and expression of the complete antibody repertoire of one or several human subjects.

Memo Therapeutics capitalizes on the MemoMAB™ platform by developing proprietary technologies and products and by offering services in the area of recombinant immunoglobulins and monoclonal antibodies.